Finder makes money from featured partners, but editorial opinions are our own.

How to buy Zoetis (ZTS) shares in Australia

Learn how to easily invest in Zoetis shares.

Zoetis Inc (ZTS) is a leading drug manufacturers - specialty & generic business with stocks listed in the US. It opened the day at US$171.57 after a previous close of US$170.9. During the day the price has varied from a low of USD169.73 to a high of USD172.27. The latest price was USD170.07 (25 minute delay). Zoetis is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Zoetis

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zoetis. Find the share by name or ticker symbol: ZTS. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zoetis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$170.9, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Zoetis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zoetis. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Zoetis stock price (NYSE:ZTS)

Use our graph to track the performance of ZTS stocks over time.

Zoetis shares at a glance

Information last updated 2024-05-24.
OpenUS$171.57
HighUS$172.27
LowUS$169.73
CloseUS$170.07
Previous closeUS$170.9
Change US$-0.83
Change % -0.4857%
Volume 1,866,735
Information last updated 2024-05-23.
52-week rangeUS$144.8 - US$200.8903
50-day moving average US$164.365
200-day moving average US$178.7448
Target priceUS$213.7
PE ratio 33.0865
Dividend yield US$1.557 (1%)
Earnings per share (TTM) US$5.2

Zoetis share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Zoetis price performance over time

Historical closes compared with the last close of $170.07

1 week (2024-05-17) -2.29%
1 month (2024-04-25) 10.90%
3 months (2024-02-23) -13.76%
6 months (2023-11-24) -5.63%
1 year (2023-05-25) 2.92%
2 years (2022-05-25) 4.32%
3 years (2021-05-25) -3.71%
5 years (2019-05-24) 66.08%

Compare trading platforms to buy Zoetis shares

Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Global shares, Options trading, US shares, ETFs
Get 30 days of $0 brokerage fees when you open your account. Receive $50 of TSLA shares and a $50 trading voucher when you deposit $200. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Saxo Invested
Saxo Invested
US$1
0.25%
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Zoetis under- or over-valued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Zoetis shares trade at around 33x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.578. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.6 billion (£2.8 billion).

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure stock profitability.

Zoetis share price volatility

Over the last 12 months, Zoetis's shares have ranged in value from as little as US$144.8 up to US$200.8903. A popular way to gauge a stock's volatility is its "beta".

ZTS.US volatility(beta: 0.86)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.857. This would suggest that Zoetis's shares are less volatile than average (for this exchange).

Zoetis financials

Revenue TTM US$8.7 billion
Operating margin TTM 36.58%
Gross profit TTM US$5.6 billion
Return on assets TTM 13.99%
Return on equity TTM 50.05%
Profit margin 27.38%
Book value 11.069
Market capitalisation US$78.5 billion

TTM: trailing 12 months

Zoetis share dividends

30%

Dividend payout ratio: 29.94% of net profits

Recently Zoetis has paid out, on average, around 29.94% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 1% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.557 per share.

While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.

Zoetis's most recent dividend payout was on 3 June 2024. The latest dividend was paid out to all shareholders who bought their shares by 17 April 2024 (the "ex-dividend date").

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.6
Total ESG percentile 49.38
Environmental score 2.72
Environmental score percentile 1
Social score 13
Social score percentile 1
Governance score 8.87
Governance score percentile 1
Level of controversy 1

Zoetis overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site